The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...
After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...
FDA's rejection of MDMA therapy for PTSD doesn't dampen hopes for other psychedelic treatments. Read more here.
The Food and Drug Administration (FDA) recently expanded approval for Spravato, an antidepressant nasal spray used to treat depression. Parkside Psychiatric Hospital has a Spravato outpatient clinic ...
In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks after J&J secured FDA monotherapy approval for its esketamine nasal spray ...
Ketamine has been used as an anesthetic before surgeries for decades, but it can also be an option for those struggling with depression and suicidal thoughts- especially when anti-depressants and talk ...
A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...
Prescription drugs can be administered in various ways. This includes oral (by mouth), enteral (into the gastrointestinal tract), mucosal (through a mucus membrane), and percutaneous (through the skin ...
The new indication allows patients the freedom to choose Spravato as a standalone therapy or alongside existing medications, enabling tailored treatment based on individual needs and tolerability.
The authors surveyed nearly 350 people about how many attempts it took to quit a substance before they were finally able to maintain their sobriety - revealing which drugs could be the most addicting.
Eli Lilly is discontinuing a Phase 2 relaxin treatment candidate for heart failure and chronic kidney disease, a spokesperson for the company confirmed to … ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback